Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Haematologica
Main Authors: Daver, Naval, Cortes, Jorge, Newberry, Kate, Jabbour, Elias, Zhou, Lingsha, Wang, Xuemei, Pierce, Sherry, Kadia, Tapan, Sasaki, Koji, Borthakur, Gautam, Ravandi, Farhad, Pemmaraju, Naveen, Kantarjian, Hagop, Verstovsek, Srdan
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2015
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004422/
https://ncbi.nlm.nih.gov/pubmed/26088933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.126821
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki